SUNLIGHT Trial: Prolonging Survival for Advanced Colorectal Cancer Patients with Trifluridine–Tipiracil and Bevacizumab - Visualmed
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
SOLSTICE trial design. *Stratified by ECOG performance status (0 vs 1... | Download Scientific Diagram
Dr Taieb on the FDA Approval of TAS-102 Plus Bevacizumab in mCRC
Frontiers | A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
Jonathan Loree on Twitter: "A2: SUNLIGHT Trial (1/5) #SUNLIGHT looked at adding bevacizumab (Avastin) to TAS-102 (Lonsurf) in ≥third line #mCRC with an OS benefit. #CRCTrialsChat @OncoAlert #CRCSM https://t.co/FaxMzsCGf6" / X
Addition of Bevacizumab to Trifluridine/Tipiracil New Standard of Care in Refractory Colorectal Cancer - The ASCO Post
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial | British Journal of Cancer
Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis - Takayuki Yoshino, Julien Taieb, Yasutoshi Kuboki, Per Pfeiffer, Amit Kumar, Howard S. Hochster, 2023
TAS-102 Shows OS Benefit With Bevacizumab in mCRC Ineligible for Intensive Therapy
Hazard ratios for death based on prespecified subgroup analysis... | Download Scientific Diagram
SUNLIGHT and FRESCO-2 Trials in Refractory Colorectal Cancer
Trifluridine/Tipiracil Plus Bevacizumab Provides Benefit in Refractory Metastatic Colorectal Cancer
New Standard of Care for Refractory Metastatic Colorectal Cancer | MedPage Today
Trifluridine/Tipiracil Plus Bevacizumab Provides Benefit in Refractory Metastatic Colorectal Cancer
ASCO GI 2023: SUNLIGHT Study
Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis - Takayuki Yoshino, Julien Taieb, Yasutoshi Kuboki, Per Pfeiffer, Amit Kumar, Howard S. Hochster, 2023
First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study | British Journal of Cancer
Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design | Future Oncology
Current Oncology | Free Full-Text | A Systematic Review and Meta-Analysis of Trifluridine/Tipiracil plus Bevacizumab for the Treatment of Metastatic Colorectal Cancer: Evidence from Real-World Series
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer | NEJM
